Tirzepatide in Mounjaro Cuts Alcohol Intake Over 50%, Study Shows

In a groundbreaking finding for those exploring the broader impacts of GLP-1 and GIP receptor agonists, tirzepatide—the active ingredient in Mounjaro—significantly reduces alcohol consumption and prevents relapse-like behavior in animal models. Published in the journal eBioMedicine, this University of Gothenburg study highlights how tirzepatide blunts the brain's reward system, specifically targeting dopamine levels in the lateral septum. Voluntary alcohol intake dropped by more than half, while binge-drinking episodes were drastically curtailed, offering new insights into potential treatments for alcohol use disorder (AUD).

The Study: Key Findings on Tirzepatide and Alcohol Consumption

Alcohol use disorder remains a major public health challenge, affecting millions worldwide with limited effective pharmacological options. The study, titled "Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents," conducted by researchers at the University of Gothenburg in collaboration with the Medical University of South Carolina, used a multifaceted approach to evaluate tirzepatide's effects.

Behavioral and Intake Paradigms

Researchers employed several established rodent models to assess alcohol-related behaviors:

• Intermittent access two-bottle choice: Mimics voluntary drinking patterns.
• Drinking in the dark: Models binge-like drinking.
• Alcohol deprivation effect: Tests relapse-like behavior after abstinence.

Results were striking: tirzepatide dose-dependently reduced voluntary alcohol consumption (P < 0.001), prevented binge drinking (P < 0.01), and blocked relapse-like drinking (P < 0.001). Even after repeated administration, efficacy was maintained (P < 0.001). Both male and female animals showed clear reductions in long-term consumption.

Molecular and Neurotransmitter Insights

Tirzepatide attenuated alcohol-induced dopamine release in the nucleus accumbens (P < 0.001), diminishing the rewarding properties of alcohol. This was measured via locomotor activity, conditioned place preference, and microdialysis. In the lateral septum—a brain region critical for motivation, reward, and relapse—the drug induced sustained synaptic depression (P < 0.05) and altered histone regulatory proteins (P < 0.05), which influence gene expression linked to addiction.

"We observed clear and robust reductions in long-term alcohol consumption, binge-like drinking, and relapse-like drinking in both male and female animals. What makes this study particularly compelling is that it also provides new insight into how this class of drugs may influence the brain's reward system," says Christian Edvardsson, a doctoral student in pharmacology at the Sahlgrenska Academy, University of Gothenburg.

These changes do not prove causation for reduced drinking but suggest they are part of tirzepatide's biological mechanisms. The study also noted metabolic effects, including reduced body weight (P < 0.001), adipose tissue mass (P < 0.01), hepatic triglycerides (P < 0.01), and pro-inflammatory cytokines (P < 0.05), aligning with tirzepatide's known profile.

How Tirzepatide Works: Targeting the Gut-Brain Axis and Reward Pathways

Tirzepatide is the first dual agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, hormones central to the gut-brain axis. Approved for type 2 diabetes and widely used off-label for weight loss as Mounjaro, it mimics satiety signals to regulate appetite and glucose.

In the context of alcohol consumption, tirzepatide modulates the mesolimbic reward circuitry. Alcohol typically spikes dopamine in reward centers like the nucleus accumbens, creating the addictive "buzz." Tirzepatide mutes this by:

• Reducing dopamine release triggered by alcohol.
• Acting on the lateral septum to dampen motivation for relapse.
• Potentially altering epigenetic factors via histone proteins.

This mechanism provides a neurobiological explanation for anecdotal reports and prior observations of reduced alcohol craving among patients on GLP-1/GIP therapies.

Comparison to Semaglutide: Building on Prior GLP-1 Research

The University of Gothenburg team previously showed that semaglutide—the active ingredient in Ozempic and Wegovy—reduces alcohol consumption in rats. Tirzepatide builds on this by offering dual agonism, potentially enhancing efficacy. While semaglutide targets GLP-1 receptors alone, tirzepatide's GIP component may broaden its impact on reward and metabolic pathways, as evidenced by stronger reductions in binge and relapse behaviors here.

Both drugs share a safety profile from extensive clinical use in diabetes and obesity, making them promising candidates for AUD research without starting from scratch.

Implications for Alcohol Use Disorder Treatment

AUD affects over 140 million people globally, with relapse rates exceeding 50% in the first year post-treatment. Current FDA-approved medications like naltrexone or acamprosate have modest efficacy. Tirzepatide's preclinical success suggests GLP-1/GIP agonists could fill this gap by addressing both behavioral and physiological aspects of addiction.

However, as Professor Elisabet Jerlhag Holm notes: "This is not yet a new treatment for alcohol use disorder. But the findings reinforce the view that drugs targeting these neural systems may be relevant to investigate further as potential treatment options."

Patient Considerations and Next Steps

For individuals with AUD who are prescribed Mounjaro for diabetes or obesity, these findings underscore the importance of monitoring alcohol intake. Patients should discuss any changes in drinking habits with their healthcare provider. Tools like Shotlee can help track symptoms, side effects, or medication adherence during therapy.

Future human trials are essential to translate rodent data. Tirzepatide's established safety—common side effects include nausea, gastrointestinal issues, and rare pancreatitis—supports rapid progression to clinical studies.

Safety Profile and Broader Metabolic Benefits

Tirzepatide's extensive study in over 10,000 patients for diabetes and obesity provides reassurance. Cardiovascular outcomes trials like SURPASS show benefits in heart health, complementing its potential in AUD. While animal models indicate reduced inflammation and liver fat from alcohol, human data on interactions remains preliminary.

Clinicians should screen for AUD in metabolic patients, as weight-loss drugs may inadvertently aid sobriety.

Key Takeaways: What This Means for Patients and Researchers

• Tirzepatide reduced voluntary alcohol intake by >50%, binge drinking, and relapse in rodents.
• Effects mediated via dopamine blunting in the lateral septum and reward pathways.
• Builds on semaglutide research, leveraging dual GLP-1/GIP agonism.
• Not a current AUD treatment but warrants human trials due to strong preclinical data and safety profile.
• Patients on Mounjaro: Monitor alcohol use and consult doctors for personalized advice.

Conclusion: A Promising Path Forward

This eBioMedicine study (DOI: 10.1016/j.ebiom.2025.106119) by Christian E. Edvardsson and colleagues marks a pivotal step in repurposing tirzepatide for AUD. By preserving the brain's reward circuitry integrity, Mounjaro's active ingredient challenges the narrative that weight-loss drugs are limited to metabolic health. Stay informed on clinical trials, and for those managing GLP-1 therapies, prioritize open discussions with providers to maximize benefits across health domains.

Original research: Open access. Authors: Christian E. Edvardsson, Louise Adermark, et al. Source: University of Gothenburg.